Joshua Zeidner: Honored to Present the Results of the Aza/Ven/Revumenib BEAT AML Study at European Hematology Association
Joshua Zeidner, Associate Professor at UNC Lineberger, shared a post on X:
“It was an honor to present the results of the Aza/Ven/Revumenib BEAT AML study at the European Hematology Association and published in JCO.
Beyond excited that these results have led to the design and development of a RP3 trial of Aza/Ven + Revumenib/placebo in newly Dx AML w/ NPM1m.”
Robert Ferris, Executive Director at UNC Lineberger Comprehensive Cancer Center, shared Joshua Zeidner‘s post on X, adding:
“Exciting results for this regimen and great example of multi-institutional team science to improve patient care.
Congratulations Dr Zeidner and Beat AML team!”
Title: Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML
Journal: JCO
Authors: Joshua F. Zeidner, Tara L. Lin, Rina Li Welkie, Emily Curran, Kristin Koenig, Wendy Stock, Yazan F. Madanat, Ronan Swords, Maria R. Baer, William Blum, Eytan M. Stein, Rebecca L. Olin, Gary Schiller, Angela Nichols, Olatoyosi Odenike, Elie Traer, Curtis Lachowiez, Vu H. Duong, Michael J. Hochman, Sheng F. Cai, Catherine Smith, Mona Stefanos, Molly Martycz, Ying Huang, Len Rosenberg, Sonja Marcus, Timothy L. Chen, Ashley O. Yocum, Brian J. Druker, Ross L. Levine, Uma Borate, John C. Byrd, Alice S. Mims
More posts featuring Joshua Zeidner on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023